COVID-19 – what have we learned?

none

przedmiot fakultatywny

Study hours involving teacher participation:

- participation in the seminar – 15 hours (including 15 hours realized in the form of e-learning)

- consultation with an academic teacher - 3 hours

Study hours involving individual student work:

- preparation for seminars - 6 hours

- reading literature – 2 hours

- preparation for test - 4 hours

The total student workload is 30 hours, which corresponds to 1 ECTS.

Student:

W1: Knows and understands the basic information regarding SARS-COV2 virus and its virulence.

W2: Knows and understands the information regarding COVID-19 symptoms, course of the disease and currently available treatment options.

Student:

U1: Is able to further develop his/her knowledge regarding SARS-COV2 and COVID19.

Student:

K1: Understands the importance of COVID-19 pandemic.

K2: Is ready to follow evidence-based medicine rules to strengthen his knowledge regarding COVID-19.

K3: Is ready to perceive and recognize his own limitations

in terms of knowledge, skills and social competences, and

self-assessment of deficits and educational needs.

Expository teaching methods:

- informative seminars

Self-education

- reading literature

The course aims to provide students with the newest information regarding novel coronavirus SARS-COV2 responsible for the pandemic and potential treatment options for COVID-19.

Class will be virtual.

During the course students get familiar with the basic information regarding novel coronavirus SARS-COV2, its structure, live cycle and virulence. During the seminar, the disease COVID-19 will be discussed along with symptoms and course of the disease. The newest treatment strategies for COVID-19 will also be discussed with particular emphasis of efficacy and safety of strategies. Eventually, the role of clinical trials and using evidence-based medicine principles during the pandemic and potential fields for development of new treatment will be presented.

1. Siemieniuk R, Rochwerg B, Agoritsas T, Lamontagne F, Leo YS, Macdonald H, Agarwal A, Zeng L, Lytvyn L, Appiah JA, Amin W, Arabi Y, Blumberg L, Burhan E, Bausch FJ, Calfee CS, Cao B, Cecconi M, Chanda D, Cooke G, Du B, Dunning J, Geduld H, Gee P, Hashimi M, Hui DS, Kabra S, Kanda S, Kawano-Dourado L, Kim YJ, Kissoon N, Kwizera A, Laake JH, Machado FR, Mahaka I, Manai H, Mino G, Nsutedu E, Pshenichnaya N, Qadir N, Sabzwari S, Sarin R, Sharland M, Shen Y, Sri Ranganathan S, Souza J, Ugarte S, Venkatapuram S, Quoc Dat V, Vuyiseka D, Stegemann M, Wijewickrama A, Maguire B, Zeraatkar D, Bartoszko J, Ge L, Brignardello-Petersen R, Owen A, Guyatt G, Diaz J, Jacobs M, Vandvik PO. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379. Update in: BMJ. 2020 Nov 19;371:m4475. PMID: 32887691.

2. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, Pardo-Hernandez H, Rochwerg B, Lamontagne F, Han MA, Liu Q, Agarwal A, Agoritsas T, Chu DK, Couban R, Darzi A, Devji T, Fang B, Fang C, Flottorp SA, Foroutan F, Ghadimi M, Heels-Ansdell D, Honarmand K, Hou L, Hou X, Ibrahim Q, Khamis A, Lam B, Loeb M, Marcucci M, McLeod SL, Motaghi S, Murthy S, Mustafa RA, Neary JD, Qasim A, Rada G, Riaz IB, Sadeghirad B, Sekercioglu N, Sheng L, Sreekanta A, Switzer C, Tendal B, Thabane L, Tomlinson G, Turner T, Vandvik PO, Vernooij RW, Viteri-García A, Wang Y, Yao L, Ye Z, Guyatt GH, Brignardello-Petersen R. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980. doi: 10.1136/bmj.m2980. Update in: BMJ. 2020 Sep 11;370:m3536. Update in: BMJ. 2020 Dec 17;371:m4852. PMID: 32732190; PMCID: PMC7390912.

Assessment methods:

- test

Assessment criteria:

- seminars: test – Pass: ≥60%; Fail: <60%

not applicable’